Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys for High-Risk AML Post-Transplant
NCT02328755Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jan 2015
- Primary completion
- Mar 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of interferon alfa in acute myeloid leukemia (AML), sponsored by University of Michigan Rogel Cancer Center. Started Jan 2015; status: completed.
02
Drugs
interferon alfa
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02328755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02328755.